Lv1
66 积分 2025-11-18 加入
Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population
1个月前
已完结
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab
1个月前
已完结
Efficacy and safety of Ebronucimab, in patients with primary hypercholesterolemia and mixed hyperlipidemia: Results from a randomized, double-blind, placebo-controlled phase III clinical study
1个月前
已完结
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
1个月前
已完结
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
1个月前
已完结
[Guideline on the diagnosis and treatment of stable coronary artery disease]
1个月前
已完结
[Chinese guidelines for lipid management (2023)]
1个月前
已完结
Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents
2个月前
已完结
Pharmacokinetics and bioequivalence of acetylcysteine granules among Chinese healthy volunteers under fasting and postprandial conditions
3个月前
已完结
皖公网安备34019202002308
